Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 30, 2022
- Revision received May 24, 2022
- Accepted May 25, 2022
- Published online July 5, 2022.
Copyright & Usage
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Author Information
- 1Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea;
- 2University of Ulsan Digestive Diseases Research Center, Seoul, Republic of Korea;
- 3Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- Correspondence to: Changhoon Yoo, MD, Ph.D., Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. Tel: +82 230101727, Fax: +82 230106961, e-mail: yooc{at}amc.seoul.kr
↵* These Authors contributed equally to this study.
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in KRAS Mutant Cholangiocarcinoma Cell Lines
- PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis
- AB668, a novel highly selective protein kinase CK2 inhibitor with a distinct anti-tumor mechanism as compared to CX-4945 and SGC-CK2-1